IL6

Across TCGA pan-cancer cohorts, IL6 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated IL6 data layer compared with 22 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher IL6 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated IL6 expression acts as an unfavorable survival marker.

SKCM, READ, and ESCA are the cancer types where IL6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	DFS	Median	All	0.105	0.761	<.001	18	view →
READ	DFS	Median	III,IV	0.182	0.745	.007	15	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

IL6–SKCM (DFS)

Open the SKCM breakdown →